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Healthcare needs of veterans have been suggested to be different from that of nonveterans and in part relates to their lifestyle in service, combat exposure, and extended overseas deployments. 8 Veterans are reported to have a higher prevalence of comorbidities and cardiovascular risk factors, such as smoking and substance abuse than nonveterans. 9, 10 These differences may in part explain differential outcomes between VA and non-VA hospitals. For example, hospitalized veterans with a primary discharge diagnosis of acute myocardial infarction have been shown to have a higher comorbidity burden than their Medicare counterparts and yet have similar mortality. 11 Similarly, among hospitalized veterans with a primary discharge diagnosis of HF, African Americans have been found to have better survival that is not fully explained by comorbidity burden or differences in healthcare utilization. 12 The beta-blocker evaluation of survival trial (BEST), a randomized controlled trial of bucindolol, a β-adrenergic-receptor blocker, in patients with advanced chronic systolic HF or HF with reduced ejection fraction (HFrEF), enrolled patients from both VA and non-VA institutions and is unique for a comparative study of patients treated for HF in VA versus non-VA hospitals. Therefore, the objective of the current study was to compare baseline characteristics and outcomes of HFrEF patients enrolled in the BEST trial receiving care at VA versus non-VA hospitals.
Methods

Data Sources and Study Population
Funded by the National Heart, Lung, and Blood Institute and the Department of Veterans Affairs Cooperative Studies Program, BEST was a randomized controlled trial of the β-blocker bucindolol in HFrEF patients with left ventricular ejection fraction (LVEF) ≤35% and New York Heart Association (NYHA) class III (92%) or IV (8%) symptoms. 13 It was conducted at 30 VA sites and 60 non-VA sites in the United States and Canada between May 1995 and December 1998, and 2708 patients were randomly assigned to either bucindolol (n=1354) or placebo (n=1354) and followed up for the primary end point of all-cause mortality.
13, 14 The trial was terminated on July 29, 1999 , by the data and safety monitoring board citing the "totality of evidence regarding the usefulness of β-blocker treatment derived from BEST and other studies." 13 The BEST protocol was approved by the institutional review board of each participating site, and the current analysis was approved by institutional review board of the University of Alabama at Birmingham.
At that time, the mean duration of follow-up was 2 years, and during that period, all-cause mortality occurred in 33% and 30% of patients in the placebo and bucindolol groups, respectively (hazard ratio [HR], 0.90; 95% confidence interval [CI], 0.78-1.02; P=0.10). However, there was a significant reduction in the risk of the secondary end point of cardiovascular death in the bucindolol group (HR, 0.86; 95% CI, 0.74-0.99). Further, there was a significant reduction in the risk of the primary end point of all-cause death in the bucindolol group among Caucasian patients (HR, 0.86; 95% CI, 0.74-0.99), but not among African Americans (HR, 1.17; 95% CI, 0.89-1.53). 13 For the purpose of the current analysis, we used a public-use version of the BEST data obtained from the National Heart, Lung, and Blood Institute that included data on 2707 participants. [15] [16] [17] [18] [19] One patient declined to be part of the completely deidentified public-use version of the data. Of the 2707 BEST participants, 918 were recruited from VA hospitals, of which 898 (98%) were male. Of the 1789 patients receiving care in non-VA hospitals, 1216 (68%) were male. We restricted our analysis to 2114 (898+1216) male participants.
Outcomes
The primary outcome of the current analysis was all-cause mortality, which was also the primary end point of the BEST trial. Secondary outcomes included cardiovascular, HF and acute myocardial infarction deaths, sudden cardiac death, and hospitalizations because of all causes and worsening HF.
Statistical Analysis
Baseline characteristics between the 2 groups were compared using chi square and student t test. Cox proportional hazard models were used to compare outcomes among patients in VA versus non-VA hospitals. After unadjusted and age-race-adjusted associations were examined, we constructed a multivariable-adjusted model, additionally adjusting for body mass index, smoking, HF duration, coronary artery disease, diabetes mellitus, hypertension, atrial fibrillation, peripheral vascular disease, chronic kidney disease, randomization to bucindolol, use of angiotensin-converting enzyme inhibitors or angiotensinreceptor blockers, digoxin, and diuretics, NYHA class symptoms, LVEF and right ventricular EF (RVEF), cardiothoracic ratio, pulmonary edema, heart rate, systolic and diastolic blood pressure, hemoglobin, serum creatinine, and serum cholesterol. We repeated the last step (multivariable-adjusted) for the secondary outcomes, except for acute myocardial infarction, for which only age and race were used as covariates because of the small number of events.
We then separately examined predictors of death among patients receiving care at VA versus non-VA hospitals using a multivariable Cox regression model in which age, sex, race, NYHA class, coronary artery disease, diabetes mellitus, hypertension, atrial fibrillation, peripheral vascular disease, chronic kidney disease, randomization to bucindolol, pulmonary edema, and LVEF and RVEF were used as covariates. Finally, we examined the VA versus non-VA differences in the primary outcome by randomization groups (bucindolol versus placebo) and by racial groups (Caucasians versus African Americans). Data analyses were performed using IBM SPSS for Windows, Rel. 
Results
Baseline Characteristics
Patients had a mean age of 61 years, and 21% were African Americans. The average age of the patients receiving care in the VA hospitals was 4 years older than that of patients receiving care at non-VA hospitals, and there were more African Americans among the patients treated in a VA hospital (Table 1) . Patients in the VA hospitals were also more likely to be smokers, have a higher prevalence of coronary artery disease, peripheral arterial disease, hypertension, and diabetes mellitus, and jugular venous distension (Table 1) . They also had a higher prevalence of regional wall motion abnormalities but similar LVEF ( Table 1 ). The median (interquartile range) duration of HF for patients receiving care at VA versus non-VA hospitals was 40 (15-76) and 35 (12-70) months, respectively.
Outcomes in the VA Versus Non-VA Hospitals
During an average of 2 years of follow-up, all-cause mortality occurred in 35% and 32% of patients receiving care in the VA and non-VA hospitals, respectively (unadjusted HR associated with VA hospitals, 1.09; 95% confidence interval CI, 0.94-1.26; Table 2 ). This association remained unchanged after adjustment for age and race (HR, 1.00; 95% CI, 0.86-1.16; Figure and Table 2 ) or multivariable adjustment (HR, 0.94; 95% CI, 0.80-1.10). Among BEST participants randomized to the bucindolol group, 34% and 30% of VA and non-VA patients, respectively, died (multivariable-adjusted HR associated with VA hospitals, 0.93; 95% CI, 0.74-1.17), whereas among BEST participants Table 3 . Compared with patients treated in the non-VA hospitals, those treated in the VA hospitals had a trend toward a lower risk of HF death or HF hospitalization. Although the risk for acute myocardial infarction death was higher among VA hospital patients, there were only 14 events.
Predictors of Outcomes in the VA Versus Non-VA Hospitals
Significant common predictors for all-cause mortality for patients receiving care in the VA and non-VA hospitals were chronic kidney disease, peripheral arterial disease, pulmonary edema, and LVEF <20% (Table 4) . Although African American race, NYHA class IV symptoms, atrial fibrillation, and RVEF <20% were significant predictors of death only among patients receiving care at non-VA hospitals, none of these differences were statistically significant. 
Discussion
Findings from the current study demonstrate that patients with advanced systolic HF receiving care at VA hospitals were older and had a higher baseline symptom and morbidity burden, yet we observed no evidence of a higher all-cause mortality or all-cause hospitalization among these patients when compared with those receiving care at non-VA hospitals. We also observed that patients receiving care at the VA hospitals had a trend toward a lower risk of HF death or HF hospitalization. In addition, major risk factors for mortality were similar between patients receiving care at the VA and non-VA hospitals. Patients receiving care at non-VA hospitals had additional risk factors that were not observed among VA patients, although these differences were not statistically significant. To the best of our knowledge, this is the first comparative study of health and outcomes of patients with advanced HFrEF receiving care at VA versus non-VA hospitals. Age is a powerful predictor of mortality in patients with HF, 20, 21 and VA hospital patients in our study were on an average 4 years older than non-VA hospital patients.
Despite their older age, VA hospital patients had a similar unadjusted mortality as that of non-VA hospital patients, suggesting that VA hospital patients in fact had a relatively lower mortality. A potential explanation for this health benefit is that VA patients were biologically younger than their chronological age and their non-VA counterparts. A biological basis for lower mortality for VA patients may be supported by the later onset of HF in these patients. Among HF patients, mean age often reflect the age of HF onset. For example, African American HF patients (versus Caucasians) who have an early onset of HF 22 are also known to have a lower mean age. 23, 24 In the age-adjusted model, this early-stage disease would be expected to explain in part the relative survival advantage of VA patients, despite a higher symptom and comorbidity Unadjusted mortality, n (%) 383 (32%) 313 (35%)
Step 1: Unadjusted 1.00 (Reference) 1.09 (0.94-1.26); P=0.274
Step 2:
Step 1+age, race (African American)
1.00 (Reference) 1.00 (0.86-1.16); P=0.978
Step 3:
Step 2+past medical history, medications, clinical findings* 1.00 (Reference) 0.94 (0.80-1.10); P=0.448
ACE indicates angiotensin-converting enzymes; ARB, angiotensin-receptor blocker; BEST, Beta-blocker Evaluation of Survival Trial; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; and RVEF, right ventricular ejection fraction.
*Includes body mass index, smoking, duration of heart failure, coronary artery disease, diabetes mellitus, hypertension, atrial fibrillation, peripheral arterial disease, chronic kidney disease, randomization to bucindolol, ACE inhibitor or ARB, digoxin, diuretic, NYHA class, LVEF, RVEF, cardiothoracic ratio, pulmonary edema, pulse, systolic and diastolic blood pressure, hemoglobin, serum creatinine, serum cholesterol, and plasma norepinephrine.
Figure.
Age-race-adjusted mortality among beta-blocker evaluation of survival trial (BEST) participants with advanced chronic systolic heart failure receiving care at the Veterans Affairs (VA) vs non-VA hospitals. ACE indicates angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; BEST, Beta-blocker Evaluation of Survival Trial; CI, confidence interval; HR, hazard ratio; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; and RVEF, right ventricular ejection fraction.
*Adjusted for age, race, body mass index, smoking, duration of heart failure, coronary artery disease, diabetes mellitus, hypertension, atrial fibrillation, peripheral arterial disease, chronic kidney disease, randomization to bucindolol, ACE inhibitor or ARB, digoxin, diuretic, NYHA class, LVEF, RVEF, cardiothoracic ratio, pulmonary edema, pulse, systolic and diastolic blood pressure, hemoglobin, serum creatinine, serum cholesterol and plasma norepinephrine.
†Adjusted for age and race only.
burden that has been shown to be associated with poor outcomes. [25] [26] [27] [28] [29] A late-stage HF may also help explain the lower HF death and HF hospitalization among VA hospital patients because pump failure is generally less common until HF is more advanced. [30] [31] [32] Other likely explanations for a relatively better outcomes for VA hospital HF patients are intense physical exercise during early military years and a more disciplined lifestyle thereafter. However, the latter notion is not supported by the higher prevalence of current smokers among the VA patients, which along with a higher prevalence of coronary heart disease may also suggest a survivor cohort effect as a potential explanation for better outcomes. Another potential explanation is differences in healthcare quality reported in VA compared with non-VA hospitals. 11, 33 Prognostic parity between HFrEF patients receiving care at VA versus non-VA hospitals is also reflected in the commonality of major risk factors for death between the 2 groups. For example, LVEF, chronic kidney disease, pulmonary edema, and peripheral arterial disease were significant predictors of death for both groups. The VA versus non-VA disparity in some of the other risk factors, which were predictors only in the non-VA setting, are intriguing and deserved further discussion. For example, there were similar number of African Americans in both groups, yet only in the non-VA setting, African Americans (versus Caucasians) had higher risk of mortality. It is not clear why African American HF patients had worse outcome in the non-VA setting. However, within the VA system, among hospitalized real-world HF patients, African American (versus Caucasians) HF patients have been shown to have lower risk-adjusted mortality that was not clearly explained by a differential healthcare utilization. 12 The lack of a mortality benefit for African American VA HF patients in our study may potentially be explained by the smaller sample size of ambulatory randomized controlled trial-eligible HFrEF patients. A similar heterogeneity in the effect of a low RVEF was also observed, despite rather similar baseline values. It has been suggested that the higher risk of death among African Americans in the BEST trial may in part be explained by their lower RVEF. 34 Several prior studies examined characteristics and outcomes of patients receiving care in the VA versus non-VA hospitals and reported similar overall finding that, despite a higher disease burden patients receiving care at VA hospitals, have similar outcomes as those receiving care at non-VA hospitals. 11, 35 However, to the best of our knowledge, this is the first report of a comprehensive comparison of characteristics and outcomes of patients with advanced HFrEF receiving care at the VA versus non-VA settings. Findings of the current study are important because they provide potential insights regarding HF care across the VA and non-VA settings. The VA versus non-VA differences in the risk factors for death, although intriguing, were not statistically significant and would need to be interpreted with caution.
Our study has several limitations. Patients in our study had an EF <35% and NYHA class III/IV and may not be generalizable to all HF patients. We had no data on depression, an important comorbidity and risk factor. Also, BEST was conducted in the 1990s, and the risk factor profile may have changed, especially the smoking rate has been reported to decline. Further, treatment practices for HFrEF have also changed during the ensuing years, although the changes would be expected to be similar in both the VA and non-VA settings. If veterans who received care in the non-VA settings had different age and duration of HF than those cared for in the VA setting, then those difference may explain some of the findings. Differences in HF causes and pathogeneses between the races may in part explain the differences in risk factors for outcome because African American HF patients are more likely to have hypertension, which may be associated with lower mortality but higher hospitalizations. Finally, it is possible that some veterans from the VA hospital group received care in non-VA hospitals, which may result in regression dilution, thus potentially underestimating the VA versus non-VA outcome differences and explaining the null findings observed in our study.
In conclusion, we observed that consistent with findings from other studies, despite older age and a higher symptom and cardiovascular morbidity burden, outcomes of HFrEF patients receiving care at VA hospitals were similar to those receiving care at non-VA hospitals, suggesting a relative survival benefit among these patients. Future studies need to examine whether primary and secondary prevention of these cardiovascular comorbid conditions may further improve survival for patients with HF receiving care at VA and non-VA hospitals. 
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